Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab in Active Systemic Lupus Erythematosus (BEGIN)
NCT00539838Phase 3Terminated
- Sponsor
- Genentech
- Start
- Dec 2007
- Primary completion
- Jul 2011
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of ocrelizumab in systemic lupus erythematosus (SLE), sponsored by Genentech. Started Dec 2007; status: terminated.
02
Drugs
ocrelizumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT00539838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00539838.